A randomized, double‐blind trial comparing pegylated interferon alfa‐2b to interferon alfa‐2b as initial treatment for chronic hepatitis C
Karen L. Lindsay, Christian Trepo, Tobias Heintges, Mitchell L. Shiffman, Stuart C. Gordon, John C. Hoefs, Eugene R. Schiff, Zachary D. Goodman, Mark Laughlin, Ruji Yao, Janice K. Albrecht – 30 December 2003 – This international, randomized, active‐controlled, parallel‐group, double‐blind dose‐finding study compared peginterferon alfa‐2b (PegIntron™) to interferon alfa‐2b for the initial treatment of compensated chronic hepatitis C.